Role of rituximab in first-line treatment of chronic lymphocytic leukemia

References

• National Cancer InstituteSurveillance epidemiology and end results stat facts sheets. cancer: chronic lymphocytic leukemia Available from: http://seer.cancer.gov/statfacts/html/clyl.html. Accessed 2010 Jul 01.
   Google Scholar
• DighieroGMaloumKDesablensBChlorambucil in indolent chronic lymphocytic leukemia. French Cooperative Group on Chronic Lymphocytic LeukemiaN Engl J Med199833821150615149593789
   PubMed Web of Science ®Google Scholar
• MaddocksKJLinTSUpdate in the management of chronic lymphocytic leukemiaJ Hematol Oncol20092291819149899
   PubMed Web of Science ®Google Scholar
• HanTEzdinliEZShimaokaKDesaiDVChlorambucil vs combined chlorambucil-corticosteroid therapy in chronic lymphocytic leukemiaCancer19733135025084693581
   PubMed Web of Science ®Google Scholar
• BinderMOttoFMertelsmannRVeelkenHTrepelMThe epitope recognized by rituximabBlood200610861975197816705086
   PubMed Web of Science ®Google Scholar
• ReffMECarnerKChambersKSDepletion of B cells in vivo by a chimeric mouse human monoclonal antibody to CD20Blood19948324357506951
   PubMed Web of Science ®Google Scholar
• MaloneyDGSmithBAppelbaumFRThe anti-tumor effect of monoclonal anti-CD20 antibody therapy includes direct anti-proliferative activity and induction of apoptosis in CD20 positive non- Hodgkin’s lymphoma cell lines [abstract]Blood199688637
   Web of Science ®Google Scholar
• JohnsonPGlennieMThe mechanisms of action of rituximab in the elimination of tumor cellsSemin Oncol2003301 Suppl 23812652458
   PubMed Web of Science ®Google Scholar
• RileyJKSliwkowskiMXCD20: a gene in search of a functionSemin Oncol2000276 Suppl 12172411225995
   PubMed Web of Science ®Google Scholar
• MaloneyDGLilesTMCzerwinskiDKPhase I clinical trial using escalating single-dose infusion of chimeric anti-CD20 monoclonal antibody (IDEC-C2B8) in patients with recurrent B-cell lymphomaBlood1994848245724667522629
   PubMed Web of Science ®Google Scholar
• McLaughlinPGrillo-LópezAJLinkBKRituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment programJ Clin Oncol1998168282528339704735
   PubMed Web of Science ®Google Scholar
• MaloneyDGGrillo-LopezAJWhiteCAIDEC-C2B8 (Rituximab) anti-CD20 antibody therapy in patients with relapsed low-grade non-Hodgkin’s lymphomaBlood1997906218821959310469
   PubMed Web of Science ®Google Scholar
• NguyenDTAmessJADoughtyHHendryLDiamondLWIDEC-C2B8 anti-CD20 (rituximab) immunotherapy in patients with low-grade non-Hodgkin’s lymphoma and lymphoproliferative disorders: evaluation of response on 48 patientsEur J Haematol1999622768210052709
   PubMed Web of Science ®Google Scholar
• AlmasriNMDuqueREIturraspeJEverettEBraylanRCReduced expression of CD20 antigen as a characteristic marker for chronic lymphocytic leukemiaAm J Hematol11924042592631380203
   PubMedGoogle Scholar
• KeatingMJO’BrienSHigh-dose rituximab therapy in chronic lymphocytic leukemiaSemin Oncol2000276 Suppl 12869011226005
   PubMed Web of Science ®Google Scholar
• O’BrienSMKantarjianHThomasDARituximab dose-escalation trial in chronic lymphocytic leukemiaJ Clin Oncol20011982165217011304768
   PubMed Web of Science ®Google Scholar
• ByrdJCMurphyTHowardRSRituximab using a thrice weekly dosing schedule in B-cell chronic lymphocytic leukemia and small lymphocytic lymphoma demonstrates clinical activity and acceptable toxicityJ Clin Oncol20011982153216411304767
   PubMed Web of Science ®Google Scholar
• ThomasDAO’BrienSGilesFJSingle agent rituxan in early stage chronic lymphocytic leukemia (CLL) [abstract]Blood2001981533
   Google Scholar
• HainsworthJDLitchySBartonJHSingle-agent rituximab as first-line and maintenance treatment for patients with chronic lymphocytic leukemia or small lymphocytic lymphoma: a phase II trial of the Minnie Pearl Cancer Research NetworkJ Clin Oncol20032191746175112721250
   PubMed Web of Science ®Google Scholar
• RaiKRPetersonBLAppelbaumFRFludarabine compared with chlorambucil as primary therapy for chronic lymphocytic leukemiaN Engl J Med2000343241750175711114313
   PubMed Web of Science ®Google Scholar
• JohnsonSSmithAGLofflerHfor The French Cooperative Group on CLLMulticentre prospective randomised trial of fludarabine versus cyclophosphamide, doxorubicin, and prednisone (CAP) for treatment of advanced-stage chronic lymphocytic leukaemiaLancet19963479013143214388676625
   PubMed Web of Science ®Google Scholar
• KeatingMJO’BrienSLernerSLong-term follow-up of patients with chronic lymphocytic leukemia (CLL) receiving fludarabine regimens as initial therapyBlood1998924116511719694704
   PubMed Web of Science ®Google Scholar
• LeporrierMChevretSCazinBRandomized comparison of fludarabine, CAP, and ChOP in 938 previously untreated stage B and C chronic lymphocytic leukemia patientsBlood20019882319232511588025
   PubMed Web of Science ®Google Scholar
• AlasSEmmanouilidesCBonavidaBInhibition of interleukin 10 by rituximab results in down-regulation of bcl-2 and sensitization of B-cell non-Hodgkin’s lymphoma to apoptosisClin Cancer Res20017370972311297268
   PubMed Web of Science ®Google Scholar
• di GaetanoNXiaoYErbaESynergism between fludarabine and rituximab revealed in a follicular lymphoma cell line resistant to the cytotoxic activity of either drug aloneBr J Haematol2001114480080911564066
   PubMed Web of Science ®Google Scholar
• SchulzHKleinSKRehwaldUPhase 2 study of a combined immunochemotherapy using rituximab and fludarabine in patients with chronic lymphocytic leukemiaBlood200210093115312012384407
   PubMed Web of Science ®Google Scholar
• ByrdJCPetersonBLMorrisonVARandomized phase 2 study of fludarabine with concurrent versus sequential treatment with rituximab in symptomatic, untreated patients with B-cell chronic lymphocytic leukemia: results from Cancer and Leukemia Group B 9712 (CALGB 9712)Blood2003101161412393429
   PubMed Web of Science ®Google Scholar
• WoyachJARuppertASHeeremaNATreatment with fludarabine and rituximab produces extended overall survival (OS) and progression-free survival (PFS) in chronic lymphocytic leukemia (CLL) without increased risk of second malignancy: long-term follow up of CALGB study 9712 [abstract]Blood200911422539
   Web of Science ®Google Scholar
• ByrdJCRaiKPetersonBLAddition of rituximab to fludarabine may prolong progression-free survival and overall survival in patients with previously untreated chronic lymphocytic leukemia: an updated retrospective comparative analysis of CALGB 9712 and CALGB 9011Blood20051051495315138165
   PubMed Web of Science ®Google Scholar
• CatovskyDRichardsSMatutesEfor UK National Cancer Research Institute (NCRI) Haematological Oncology Clinical Studies GroupNCRI Chronic Lymphocytic Leukaemia Working GroupAssessment of fludarabine plus cyclophosphamide for patients with chronic lymphocytic leukaemia (the LRF CLL4 Trial): a randomised controlled trialLancet2007370958323023917658394
   PubMed Web of Science ®Google Scholar
• EichhorstBFBuschRHopfingerGfor German CLL Study GroupFludarabine plus cyclophosphamide versus fludarabine alone in first-line therapy of younger patients with chronic lymphocytic leukemiaBlood2006107388589116219797
   PubMed Web of Science ®Google Scholar
• FlinnIWNeubergDSGreverMRPhase III trial of fludarabine plus cyclophosphamide compared with fludarabine for patients with previously untreated chronic lymphocytic leukemia: US Intergroup Trial E2997J Clin Oncol200725779379817283364
   PubMed Web of Science ®Google Scholar
• KeatingMJO’BrienSAlbitarMEarly results of a chemoimmunotherapy regimen of fludarabine, cyclophosphamide, and rituximab as initial therapy for chronic lymphocytic leukemiaJ Clin Oncol200523184079408815767648
   PubMed Web of Science ®Google Scholar
• TamCSO’BrienSWierdaWLong-term results of the fludarabine, cyclophosphamide, and rituximab regimen as initial therapy of chronic lymphocytic leukemiaBlood2008112497598018411418
   PubMed Web of Science ®Google Scholar
• HallekMFingerle-RowsonGFinkAMFirst-Line treatment with fludarabine (F), cyclophosphamide (C), and rituximab (R) (FCR) improves overall survival (OS) in previously untreated patients (pts) with advanced chronic lymphocytic leukemia (CLL): results of a randomized phase III trial on behalf of an International Group of Investigators and the German CLL Study Group [abstract]Blood20091142253519451549
   PubMed Web of Science ®Google Scholar
• O’BrienSWierdaWGFaderlSFCR-3 as frontline therapy for patients with chronic lymphocytic leukemia (CLL). [abstract]Blood2005106112117
   Google Scholar
• FoonKABoyiadzisMLandSRChemoimmunotherapy with low-dose fludarabine and cyclophosphamide and high dose rituximab in previously untreated patients with chronic lymphocytic leukemiaJ Clin Oncol200927449850319075274
   PubMed Web of Science ®Google Scholar
• KayNEGeyerSMCallTGCombination chemoimmunotherapy with pentostatin, cyclophosphamide, and rituximab shows significant clinical activity with low accompanying toxicity in previously untreated B chronic lymphocytic leukemiaBlood2007109240541117008537
   PubMed Web of Science ®Google Scholar
• KayNEWuWKabatBPentostatin and rituximab therapy for previously untreated patients with B-Cell chronic lymphocytic leukemiaCancer201011692180218720187101
   PubMed Web of Science ®Google Scholar
• BoschFAbrisquetaPVillamorNRituximab, fludarabine, cyclophosphamide, and mitoxantrone: a new, highly active chemoimmunotherapy regimen for chronic lymphocytic leukemiaJ Clin Oncol200992027274578458419704063
   PubMed Web of Science ®Google Scholar
• BoschFFerrerAVillamorNFludarabine, cyclophosphamide, and mitoxantrone as initial therapy of chronic lymphocytic leukemia: High response rate and disease eradicationClin Cancer Res200814115516118172266
   PubMed Web of Science ®Google Scholar
• BellosilloBVillamorNColomerDIn vitro evaluation of fludarabine in combination with cyclophosphamide and/or mitoxantrone in B-cell chronic lymphocytic leukemiaBlood19999482836284310515887
   PubMed Web of Science ®Google Scholar
• BellosilloBColomerDPonsGGilJMitoxantrone, a topoisomerase II inhibitor, induces apoptosis of B- chronic lymphocytic leukaemia cellsBr J Haematol199810011421469450803
   PubMed Web of Science ®Google Scholar
• BoschFFerrerALopez-GuillermoAFludarabine, cyclophosphamide and mitoxantrone in the treatment of resistant or relapsed chronic lymphocytic leukaemiaBr J Haematol2002119497698412472576
   PubMed Web of Science ®Google Scholar
• HendryLBowenAMatutesESwansburyJCatovskyDFludarabine, cyclophosphamide and mitoxantrone in relapsed or refractory chronic lymphocytic leukemia and low grade non-Hodgkin’s lymphomaLeuk Lymphoma200445594595015291353
   PubMed Web of Science ®Google Scholar
• ChesonBDBennettJMGreverMfor National Cancer Institute-sponsored Working Group guidelines for chronic lymphocytic leukemiaRevised guidelines for diagnosis and treatmentBlood19968712499049978652811
   PubMed Web of Science ®Google Scholar
• FaderlSWierdaWO’BrienSFerrajoliALernerSKeatingMJFludarabine, cyclophosphamide, mitoxantrone plus rituximab (FCM-R) in frontline CLL < 70 YearsLeuk Res201034328428819646755
   PubMed Web of Science ®Google Scholar
• KathRBlumenstengelKFrickeHJBendamustine monotherapy in advanced and refractory chronic lymphocytic leukemiaJ Cancer Res Clin Oncol20011271485411206271
   PubMed Web of Science ®Google Scholar
• AivadoMBeckerKNeiseMBendamustine is an efficient and well-tolerated option in the palliation of pretreated B-cell chronic lymphocytic leukemias [abstract]Proc Am Soc Clin Oncol200120306
   Google Scholar
• ChowKUSommerladWDBoehrerSAnti-CD20 antibody (IDEC-C2B8, rituximab) enhances efficacy of cytotoxic drugs on neoplastic lymphocytes in vitro: role of cytokines, complement, and caspasesHaematologica2002871334311801463
   PubMed Web of Science ®Google Scholar
• FischerKBendamustine in combination with rituximab (BR) for patients with relapsed chronic lymphocytic leukemia (CLL). A multicentre phase II trial of the German CLL Study Group (GCLLSG) [abstract]Blood20081121133018451308
   PubMed Web of Science ®Google Scholar
• FischerKBendamustine combined with rituximab (BR) in first-line therapy of advanced CLL: a multicenter phase II trial of the German CLL Study Group (GCLLSG) [abstract]Blood200911422205
   Web of Science ®Google Scholar
• National Institutes of HealthFludarabine, cyclophosphamide, and rituximab or bendamustine and rituximab in treating patients with previously untreated B-cell chronic lymphocytic leukemia Available from: http://clinicaltrials.gov/ct2/show/NCT00769522?term=bendamustine+and+fludarabine&rank=3. Accessed 2010 Jul 07.
   Google Scholar
• WierdaWGO’BrienSFerrajoliACombined cyclophosphamide, fludarabine, alemtuzumab, and rituximab (CFAR), an active frontline regimen for high-risk patients with CLL [abstract]Blood200711011628
   Web of Science ®Google Scholar
• ParikhSAKeatingMO’BrienSFrontline combined chemoimmunotherapy with fludarabine, cyclophosphamide, alemtuzumab and rituximab (CFAR) in high-risk chronic lymphocytic leukemia [abstract]Blood200911422208
   Web of Science ®Google Scholar
• OsterborgADyerMJBunjesDfor European Study Group of Campath-1H Treatment in Chronic Lymphocytic LeukemiaPhase II multicenter study of human CD52 antibody in previously treated chronic lymphocytic leukemiaJ Clin Oncol1997154156715749193354
   PubMed Web of Science ®Google Scholar
• KeatingMJFlinnIJainVTherapeutic role of alemtuzumab (Campath-1H) in patients who have failed fludarabine: results of a large international studyBlood200299103554356111986207
   PubMed Web of Science ®Google Scholar
• OsterborgAFassasASAnagnostopoulosADyerMJCatovskyDMellstedtHHumanized CD52 monoclonal antibody Campath-1H as first-line treatment in chronic lymphocytic leukaemiaBr J Haematol19969311511538611450
   PubMed Web of Science ®Google Scholar
• HillmenPSkotnickiABRobakTAlemtuzumab compared with chlorambucil as first-line therapy for chronic lymphocytic leukemiaJ Clin Oncol200725355616562317984186
   PubMed Web of Science ®Google Scholar
• LozanskiGHeeremaNAFlinnIWAlemtuzumab is an effective therapy for chronic lymphocytic leukemia with p53 mutations and deletionsBlood200410393278328114726385
   PubMed Web of Science ®Google Scholar
• OsujiNCDel GiudiceIMatutesEWotherspoonACDeardenCCatovskyDThe efficacy of alemtuzumab for refractory chronic lymphocytic leukemia in relation to cytogenetic abnormalities of p53Haematologica200590101435143616219582
   PubMed Web of Science ®Google Scholar
• ZentCSCallTGShanafeltTDEarly treatment of high-risk chronic lymphocytic leukemia with alemtuzumab and rituximabCancer200811382110211818759253
   PubMed Web of Science ®Google Scholar
• HillmenPGribbenJGFollowsGAAn open-label phase II study to investigate the safety and efficacy of rituximab plus chlorambucil in previously untreated patients with CD20-positive B-Cell chronic lymphocytic leukaemia (CLL) [abstract]Blood2009114223428
   Web of Science ®Google Scholar
• CastroJEJamesDFSandoval-SusJDRituximab in combination with high-dose methylprednisolone for the treatment of chronic lymphocytic leukemiaLeukemia200923101779178919693094
   PubMed Web of Science ®Google Scholar
• MaloneyDGGrillo-LópezAJBodkinDJIDEC-C2B8: results of a phase I multiple-dose trial in patients with relapsed non-Hodgkin’s lymphomaJ Clin Oncol19971510326632749336364
   PubMed Web of Science ®Google Scholar
• WinklerUJensenMManzkeOCytokine-release syndrome in patients with B-cell chronic lymphocytic leukemia and high lymphocyte counts after treatment with an anti-CD20 monoclonal antibody (Rituximab, IDEC-C2B8)Blood19999472217222410498591
   PubMed Web of Science ®Google Scholar
• LimLCKohLPTanPFatal cytokine release syndrome with chimeric anti-CD20 monoclonal antibody rituximab in a 71-year-old patient with chronic lymphocytic leukemiaJ Clin Oncol19991761962196310561242
   PubMed Web of Science ®Google Scholar
• ByrdJCWaselenkoJKManeatisTJRituximab therapy in hematologic malignancy patients with circulating blood tumor cells: association with increased infusion related side effects and rapid blood tumor clearanceJ Clin Oncol199917379179510071268
   PubMed Web of Science ®Google Scholar
• JensenMWinklerUManzkeODiehlVEngertARapid tumor lysis in a patient with B-cell chronic lymphocytic leukemia and lymphocytosis treated with an anti-CD20 monoclonal antibody (IDEC-C2B8, rituximab)Ann Hematol1998771–289919760161
   PubMed Web of Science ®Google Scholar
• LawJKHoJKHoskinsPJFatal reactivation of hepatitis B post-chemotherapy for lymphoma in a hepatitis B surface antigen-negative, hepatitis B core antibody-positive patient: potential implications for future prophylaxis recommendationsLeuk Lymphoma20054671085108916019563
   PubMed Web of Science ®Google Scholar
• WesthoffTHJochimsenFSchmittelAFatal hepatitis B virus reactivation by an escape mutant following rituximab therapyBlood200310251930
   PubMed Web of Science ®Google Scholar
• NiscolaPDel PrincipeMIMaurilloLFulminant B hepatitis in a surface antigen-negative patient with B-cell chronic lymphocytic leukaemia after rituximab therapyLeukemia200519101840184116094417
   PubMed Web of Science ®Google Scholar
• CarsonKREvensAMRicheyEAProgressive multifocal leukoencephalopathy after rituximab therapy in HIV-negative patients: a report of 57 cases from the Research on Adverse Drug Events and Reports projectBlood2009113204834484019264918
   PubMed Web of Science ®Google Scholar
• SehnLHDonaldsonJFilewichARapid infusion rituximab in combination with corticosteroid-containing chemotherapy or as maintenance therapy is well tolerated and can safely be delivered in the community settingBlood2007109104171417317244675
   PubMed Web of Science ®Google Scholar
• SalarACasaoDCerveraMRapid infusion of rituximab with or without steroid-containing chemotherapy: 1-yr experience in a single institutionEur J Haematol200677433834016856919
   PubMed Web of Science ®Google Scholar
• TuthillMCrookTCorbetTKingJWebbARapid infusion of rituximab over 60 minEur J Haematol200982432232519220420
   PubMed Web of Science ®Google Scholar
• ProvencioMCerdeiraSBonillaFSánchezAEspañaPRapid-infusion rituximab in lymphoma treatmentAnn Oncol20061761027102816322113
   PubMed Web of Science ®Google Scholar